Prevalence of Hepatitis C Among Migrants: A Systematic Review and Meta-Analysis

The World Health Organisation has targeted the Hepatitis C virus (HCV) to be eliminated as a public health threat by 2030. Equitable access to HCV testing and treatment services is important in achieving this goal. Migrants often face barriers to accessing health services, and understanding HCV prevalence among this population can support planning for elimination. This systematic review aimed to estimate HCV prevalence among migrants residing in high-income countries with low/intermediate HCV prevalence. Scopus, PubMed, PsycINFO and Cochrane Library were searched for peer-reviewed articles published in English between 2015 and 2024. The studies' quality was assessed using The Joanna Briggs Institute (JBI) Critical Appraisal Tools. A proportional meta-analysis was used to estimate HCV prevalence. Thirty-seven studies were included in this review. Seventeen studies included both people < 18 and ≥ 18 years old, 16 studies only included people ≥ 18 years old, and three studies included people aged 18 and younger. The pooled prevalence of HCV antibody (anti-HCV) and RNA (HCV-RNA) were 1.5% (95% CI, 1.1%–2.0%) and 0.6% (95% CI, 0.4%–0.9%), respectively. The prevalence of anti-HCV was higher among males (1.9%) than females (0.6%). Among refugees and asylum seekers, the prevalence of anti-HCV and HCV-RNA were 1.4% and 0.7%, respectively. The prevalence of HCV among migrants is comparable with that among the general population of the destination countries. Given the barriers migrants, especially refugees and asylum seekers, face in accessing health services, their access to HCV information, testing and treatment should be facilitated.